LAM-001
Small molecule
Evidence outlook
Mid-stage studies underway, no completed readout
Phase 2 studies are registered but none has completed a readout, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.
Also in development:Bronchiolitis Obliterans Syndrome · Phase 2
Company guidance: data expected first quarter of 2028 (Quince Therapeutics, 14 Aug 2026). “Society (ATS) in May 2026, the company has advanced LAM-001 into a Phase 2b PH-ILD trial and data is anticipated in the first quarter of 2028.” Source ↗
The company’s own stated timing, shown beside the ClinicalTrials.gov estimate. Neither is a confirmed date.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT05798923 NCT05798923 · Pulmonary Hypertension Due to Lung Diseases and Hypoxia Registry: NCT05798923 | 2 | To determine the change in PVR at 24 weeks 2028-03 | In progress: results expected 1 Mar 2028 | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 2 (3)
What this study did
What this study did
What this study did
Competitive landscape
Other mTOR (inhibitor) drugs
1 other tracked programme targets this mechanism, none of them ahead of this one.
This drug's own stage for Pulmonary Hypertension Associated with Interstitial Lung Disease: Phase 2. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| LAM-001: this drug | Phase 2 | Small molecule | mTOR (inhibitor) | not yet graded | No reviewed efficacy summary in this indication | |
| Treprostinil (Tyvaso DPI) | Approved | Small molecule | IP receptor (prostacyclin pathway) | not yet graded | No reviewed efficacy summary in this indication | |
| Treprostinil (Tyvaso) | Approved | Small molecule | IP receptor (prostacyclin pathway) | Reliable signal | NCT02630316: Change in peak 6-minute walk distance from baseline to week 16: inhaled treprostinil median +6.0 m vs placebo -9.0 m (n=163 each); Hodges-Lehmann difference 21.0 m (95% CI 7.0 to 37.0), p=0.0043 (CT.gov posted results). | |
| Treprostinil (Yutrepia, Liquidia) | Approved | Small molecule | IP receptor (prostacyclin pathway) | not yet graded | No reviewed efficacy summary in this indication | |
| Mosliciguat | Phase 3 | Small molecule | Soluble guanylate cyclase | not yet graded | No reviewed efficacy summary in this indication | |
| Treprostinil (L606) | Phase 3 | Small molecule | IP receptor (prostacyclin pathway) | not yet graded | No reviewed efficacy summary in this indication | |
| Fc-Relaxin Fusion Protein (TX45) | Phase 2 | Protein / enzyme therapeutic | Relaxin receptor (RXFP1) / relaxin | not yet graded | No reviewed efficacy summary in this indication | |
| Mirivadelgat | Phase 2 | Small molecule | ALDH2 | not yet graded | No reviewed efficacy summary in this indication | |
| Onatasertib | Phase 2(overall) | Small molecule | mTOR (inhibitor) | Weak signal(overall) | No reviewed efficacy summary in this indication |
Upcoming events
(3 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow LAM-001 to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.